Lynparza more than doubled the time without radiographic disease progression in patients with BRCA1/2- or ATM-mutated metastatic castration-resistant prostate cancer
AstraZeneca and MSD’s Lynparza reduced the risk of disease progression ordeath by 51% in men with homologous recombination repair (HRR) gene mutations First positive Phase III trial testing a targeted treatment in biomarker-selected prostate cancer patientsAstraZeneca and MSD Inc., Kenilworth, N.J., US (MSD: known as Merck & Co., Inc. inside the US and Canada) today presented detailed results from the Phase III PROfound trial in 387 men with metastatic castration-resistant prostate cancer (mCRPC) who have a mutation in their homologous recombination repair (HRRm) genes and whose disease